Crown Bioscience Buys PDX Unit from Molecular Response

Crown Bioscience, a US-China preclinical CRO with a focus on oncology, added to its offerings by acquiring diagnostic oncology assets from Molecular Response of San Diego. Crown bought MRL’s PDX bank of several hundred established models for in vivo pharmacology services along with several other models under development. It also acquired access to 8,000 viable human tumors for the next two years. And Crown will take over MRL’s San Diego-based PDX service operations, which will become a Crown global center of excellence for Translational Oncology. The price was not disclosed. More details.... Share this with colleagues: // //